Article Information
History
- June 9, 2020.
Article Versions
- Version 1 (June 4, 2020 - 02:51).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Melinda Wang1,4,
- Xiaojia Guo, PhD1,4,
- Hyung J Chun, MD1,4,
- Alfred Ian Lee, MD, PhD1,4,
- Charles Cha, MD2,4,
- Fred Gorelick, MD1,3,4 and
- Gary V Desir, MD1,4,*
- 1Department of Medicine
- 2Surgery
- 3Cell Biology
- 4Yale School of Medicine
- 5New Haven, CT and VA CT Healthcare, West Haven, CT
- ↵*Correspondence should be addressed to
, Gary Desir M.D. Section of Nephrology, Department of Medicine, Yale School of Medicine, P.O. Box 208029, New Haven, CT 06520-8029, Voice (203) 785-4119, E-Mail: gary.desir{at}yale.edu
Posted June 09, 2020.
Decreased plasma levels of the survival factor renalase are associated with worse outcomes in COVID-19
